|

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

RECRUITINGPhase 4Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 4
SponsorEli Lilly and Company
Started2025-11-24
Est. completion2029-07
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07247084

Summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
* Have an increased waist to height ratio (defined by \>0.5)
* Have at least one weight related comorbid condition
* Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)

Exclusion Criteria:

* Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
* Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

Conditions2

DiabetesObesity

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.